These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21371588)

  • 1. Predicting the success of fragment screening by X-ray crystallography.
    Davies DR; Begley DW; Hartley RC; Staker BL; Stewart LJ
    Methods Enzymol; 2011; 493():91-114. PubMed ID: 21371588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei.
    Begley DW; Hartley RC; Davies DR; Edwards TE; Leonard JT; Abendroth J; Burris CA; Bhandari J; Myler PJ; Staker BL; Stewart LJ
    J Struct Funct Genomics; 2011 Jul; 12(2):63-76. PubMed ID: 21359640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment screening of infectious disease targets in a structural genomics environment.
    Begley DW; Davies DR; Hartley RC; Edwards TE; Staker BL; Van Voorhis WC; Myler PJ; Stewart LJ
    Methods Enzymol; 2011; 493():533-56. PubMed ID: 21371605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening Ligands by X-ray crystallography.
    Davies DR
    Methods Mol Biol; 2014; 1140():315-23. PubMed ID: 24590727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An ensemble of structures of Burkholderia pseudomallei 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase.
    Davies DR; Staker BL; Abendroth JA; Edwards TE; Hartley R; Leonard J; Kim H; Rychel AL; Hewitt SN; Myler PJ; Stewart LJ
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Sep; 67(Pt 9):1044-50. PubMed ID: 21904048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment Hits: What do They Look Like and How do They Bind?
    Giordanetto F; Jin C; Willmore L; Feher M; Shaw DE
    J Med Chem; 2019 Apr; 62(7):3381-3394. PubMed ID: 30875465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystallographic analysis of TPP riboswitch binding by small-molecule ligands discovered through fragment-based drug discovery approaches.
    Warner KD; Ferré-D'Amaré AR
    Methods Enzymol; 2014; 549():221-33. PubMed ID: 25432751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.
    Recht MI; Sridhar V; Badger J; Bounaud PY; Logan C; Chie-Leon B; Nienaber V; Torres FE
    J Biomol Screen; 2014 Apr; 19(4):497-507. PubMed ID: 24375910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing conformational states of glutaryl-CoA dehydrogenase by fragment screening.
    Begley DW; Davies DR; Hartley RC; Hewitt SN; Rychel AL; Myler PJ; Van Voorhis WC; Staker BL; Stewart LJ
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Sep; 67(Pt 9):1060-9. PubMed ID: 21904051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.
    Coutard B; Decroly E; Li C; Sharff A; Lescar J; Bricogne G; Barral K
    Antiviral Res; 2014 Jun; 106():61-70. PubMed ID: 24704437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lead generation and examples opinion regarding how to follow up hits.
    Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
    Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystallographic fragment screening.
    Badger J
    Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing a diverse high-quality library for crystallography-based FBDD screening.
    Tounge BA; Parker MH
    Methods Enzymol; 2011; 493():3-20. PubMed ID: 21371585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space.
    Rudling A; Gustafsson R; Almlöf I; Homan E; Scobie M; Warpman Berglund U; Helleday T; Stenmark P; Carlsson J
    J Med Chem; 2017 Oct; 60(19):8160-8169. PubMed ID: 28929756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of 2-amino-4-hydroxypyrimidine-5-carboxylates and binding to Burkholderia pseudomallei 2-C-methyl-d-erythritol-2,4-cyclodiphosphate synthase.
    Watkins SM; Ghose D; Blain JM; Grote DL; Luan CH; Clare M; Meganathan R; Horn JR; Hagen TJ
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126660. PubMed ID: 31521478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein X-ray Crystallography and Drug Discovery.
    Maveyraud L; Mourey L
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32106588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of hit generation and structural characterization in fragment-based ligand discovery.
    Larsson A; Jansson A; Åberg A; Nordlund P
    Curr Opin Chem Biol; 2011 Aug; 15(4):482-8. PubMed ID: 21724447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-based drug discovery using rational design.
    Jhoti H
    Ernst Schering Found Symp Proc; 2007; (3):169-85. PubMed ID: 18510103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.